There are multiple possible reasons for the contrary results: selection differences for Nrf2 antibodies, different types of Nrf2-related cells that play a role in neuroprotection, different Nrf2 knockout lines, whether the expression of protective Nrf2-activated enzymes is sufficiently high, whether the Nrf2 activator can pass through the BBB and directly activate Nrf2, differences in detected ischemic brain tissue sites, and differences in detected ischemia time points and markers. This evidence concerns the gene NFE2L2 and ischemia.